Compare Okta, Inc. (OKTA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Okta, Inc. vs BIO-TECHNE Corp — how do they compare? Okta, Inc. trades at $136.11 (market cap $24.63B), while BIO-TECHNE Corp trades at $71.73 (market cap $11.16B). The key difference: Okta, Inc. is far larger — about 2.2× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals.
| OKTA | TECH | |
|---|---|---|
Market Cap | $24.63B | $11.16B |
Sector | Technology | Health |
52-Week High | $154.62 | $72.12 |
52-Week Low | $62.93 | $43.31 |
Enterprise Value | $22.45B | $11.24B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OKTA trades at $141.63, down 5.17% in the last session amid broader market volatility. The stock shows strong fundamental improvement with revenue growing to $2.61B in 2025 and achieving positive net income of $28M after years of losses. Technical indicators suggest a bullish trend with strong moving average signals, while oscillators remain neutral. Recent analyst coverage remains overwhelmingly positive with 37 buy ratings versus 2 sell ratings.
The outlook remains constructive given OKTA's position in the growing cybersecurity sector and improving profitability. Key risks include high valuation multiples (P/E of 107.54) and competitive pressures. The consensus price target of $127.96 suggests potential downside from current levels, though the high target of $175.00 indicates significant upside potential if execution continues.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
